GleamWall
中文EN

NVCT Nuvectis Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1875558 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-98.8%
TTM EPS YoY-46.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-67.0%
ROA-57.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$18.15M$12.92M
SG&A expense$9.42M$6.93M
Operating income-$27.57M-$19.85M
Net income-$26.44M-$19.00M
EPS (basic)-1.32-1.11
EPS (diluted)-1.32-1.11
Dividends declared per share0.000.00
Weighted avg. shares (diluted)21.81M17.11M
Balance sheet
Cash & equivalents$31.63M$18.53M
Current assets$31.71M$18.61M
Total assets$31.71M$18.61M
Current liabilities$13.30M$8.89M
Total liabilities$13.30M$8.89M
Shareholders' equity$18.41M$9.71M
Shares outstanding25.68M19.50M
Cash flow statement
Operating cash flow-$16.01M-$12.25M
Investing cash flow—$0
Financing cash flow$29.11M$11.65M
Stock-based compensation$6.03M$4.86M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.